These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37699957)

  • 41. Associations of blood UCH-L1 and NfL levels with cognitive dysfunction in Parkinson's disease patients.
    Dong L; Chang Q; Ma J; Liu C; Guo D; Li X; Yang D; Fan Y; Liang K; Li D; Gu Q
    Neurosci Lett; 2023 May; 804():137219. PubMed ID: 37023526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The association of serum neurofilament light chains with early symptoms related to Parkinson's disease: A cross-sectional study.
    Wang X; Yang X; He W; Song X; Zhang G; Niu P; Chen T
    J Affect Disord; 2023 Dec; 343():144-152. PubMed ID: 37805158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity.
    Huang Y; Huang C; Zhang Q; Shen T; Sun J
    BMC Neurol; 2022 Jan; 22(1):39. PubMed ID: 35086487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes.
    Ygland Rödström E; Mattsson-Carlgren N; Janelidze S; Hansson O; Puschmann A
    J Parkinsons Dis; 2022; 12(2):571-584. PubMed ID: 34806619
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort.
    Jeong EH; Lee JY; Han SK; Song YS
    Front Neurol; 2023; 14():1276251. PubMed ID: 37954645
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combining biomarkers for prognostic modelling of Parkinson's disease.
    Vijiaratnam N; Lawton M; Heslegrave AJ; Guo T; Tan M; Jabbari E; Real R; Woodside J; Grosset K; Chelban V; Athauda D; Girges C; Barker RA; Hardy J; Wood N; Houlden H; Williams N; Ben-Shlomo Y; Zetterberg H; Grosset DG; Foltynie T; Morris HR;
    J Neurol Neurosurg Psychiatry; 2022 May; 93(7):707-15. PubMed ID: 35577512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
    Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
    Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurofilament light chain level in plasma extracellular vesicles and Parkinson's disease.
    Chung CC; Chan L; Chen JH; Bamodu OA; Hong CT
    Ther Adv Neurol Disord; 2020; 13():1756286420975917. PubMed ID: 33335563
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
    Chen CH; Lee BC; Lin CH
    J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study.
    Pötter-Nerger M; Dutke J; Lezius S; Buhmann C; Schulz R; Gerloff C; Kuhle J; Choe CU
    J Neural Transm (Vienna); 2022 Mar; 129(3):295-300. PubMed ID: 35072765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
    Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder.
    Zhang X; Ma L; Liang D; Song B; Chen J; Huang Y; Xu L; Zhao P; Wu W; Zhang N; Xue R
    J Parkinsons Dis; 2023; 13(4):485-499. PubMed ID: 37182898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease.
    Kozlovski T; Mitelpunkt A; Thaler A; Gurevich T; Orr-Urtreger A; Gana-Weisz M; Shachar N; Galili T; Marcus-Kalish M; Bressman S; Marder K; Giladi N; Benjamini Y; Mirelman A
    Front Neurol; 2019; 10():531. PubMed ID: 31164863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single molecule array measures of LRRK2 kinase activity in serum link Parkinson's disease severity to peripheral inflammation.
    Yuan Y; Li H; Sreeram K; Malankhanova T; Boddu R; Strader S; Chang A; Bryant N; Yacoubian TA; Standaert DG; Erb M; Moore DJ; Sanders LH; Lutz MW; Velmeshev D; West AB
    bioRxiv; 2024 Apr; ():. PubMed ID: 38659797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Temporal trajectory of biofluid markers in Parkinson's disease.
    Baek MS; Lee MJ; Kim HK; Lyoo CH
    Sci Rep; 2021 Jul; 11(1):14820. PubMed ID: 34285331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort.
    Simuni T; Merchant K; Brumm MC; Cho H; Caspell-Garcia C; Coffey CS; Chahine LM; Alcalay RN; Nudelman K; Foroud T; Mollenhauer B; Siderowf A; Tanner C; Iwaki H; Sherer T; Marek K;
    NPJ Parkinsons Dis; 2022 Oct; 8(1):140. PubMed ID: 36273008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease.
    DeBroff J; Omer N; Cohen B; Giladi N; Kestenbaum M; Shirvan JC; Cedarbaum JM; Gana-Weisz M; Goldstein O; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord Clin Pract; 2023 Apr; 10(4):606-616. PubMed ID: 37070047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinson's Disease.
    Imarisio A; Pilotto A; Garrafa E; Conforti F; Masciocchi S; Turrone R; Gipponi S; Cottini E; Rizzetti MC; Porrini V; Gussago C; Pizzi M; Guadagni F; Zetterberg H; Ashton NJ; Hye A; Padovani A
    Neurodegener Dis; 2021; 21(5-6):109-116. PubMed ID: 35287127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.